Molecule
- Sitagliptin (50 mg): A DPP-4 inhibitor that increases incretin hormone levels, leading to improved insulin secretion and reduced blood glucose.
- Metformin Hydrochloride (500 mg): A biguanide that lowers glucose production in the liver, enhances peripheral insulin sensitivity, and delays intestinal glucose absorption.
Category
Antidiabetic – DPP-4 Inhibitor + Biguanide
Sitagliptin 50 mg + Metformin Hydrochloride 500 mg
Sitalor M 50/500 is a combination of Sitagliptin (50 mg) and Metformin Hydrochloride (500 mg), designed to provide effective glycemic control in patients with Type 2 Diabetes Mellitus. Sitagliptin enhances insulin secretion and reduces glucagon levels, while Metformin improves insulin sensitivity and decreases hepatic glucose production.
Benefits
✔ Improves insulin sensitivity and glycemic control
✔ Reduces fasting and postprandial blood sugar levels
✔ Enhances pancreatic beta-cell function
Storage & Precautions
- Store below 30°C in a dry place
- Not recommended for patients with severe renal or hepatic impairment
- Avoid excessive alcohol consumption
Packaging
10 x 10 Tablets per box
For medical use only. Consult a doctor before use.